



**ALIKO
SCIENTIFIC**
Next Generation Cancer Diagnostics



▶ **Press Release**

Update on the suspension of trading of ALIKO shares on Euronext Growth Paris and postponement of the publication of the 2025 annual financial report

Paris, June 19, 2026 – 8:45 pm CEST – Aliko Scientific SA (Ikonisys SA – Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today provides an update on the suspension of trading of its shares on Euronext Growth Paris and announces the postponement of the publication of its 2025 annual financial report, initially scheduled for June 19, 2026, as announced in the press release dated April 23, 2026.

Trading of the Company's shares on Euronext Growth Paris has been suspended since Monday, June 15, 2026, in connection with the pending publication of the Company's 2025 annual financial report. The Company expects trading to resume following publication of the 2025 annual financial report, in accordance with applicable market procedures.

The postponement is due to additional time required to complete the finalization of the annual financial report and the related audit procedures. The Company is actively working with its statutory auditors and internal teams to finalize the report as quickly as possible, while ensuring the required level of accuracy, completeness and transparency.

The publication of the 2025 annual financial report is expected by July 31, 2026.

The Company will keep the market informed of any significant development and of the publication of the annual financial report.

About ALIKO SCIENTIFIC (Ikonisys SA)

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: www.ikonisys.com

About HOSPITEX

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics.

For more information, visit: www.hospitex.com

Contacts

Ikonisys

Alessandro Mauri
CFO
investors@ikonisys.com

NewCap

Louis-Victor Delouvrier/Thomas Cozzolino
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94

NewCap

Nicolas Mérigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.